Deep Longevity’s new US telehealth platform, Accrua, ties treatment plans to a blood-based aging score and re-tests every ...

The Austin-based microbiome testing company raised a $33M Series B, and adults now outnumber babies in its testing volume.

The Parkinson’s enzyme therapy is still heading toward the clinic, and the deal could grow by up to $1.17bn in milestone ...

Swedish biotech will present the Phase II ADVANCE trial design for vaccine candidate ALZ-101 at Alzheimer’s disease ...

First-in-human ER-100 data support dose escalation, with early visual-field signals in two of three glaucoma patients.

Designerly's Cooper Adwin looks at why generative AI Is re-engineering skin rejuvenation and phasing out animal collagen.

Pharma has the podium as Novo and Lilly stop talking about GLP-1 longevity and start measuring it, bringing early aging data ...

A five-year NIA grant puts UCLA Health in charge of checking whether AI tools for Alzheimer’s care work before they spread.

AbbVie’s JUVMO (tavapadon) targets dopamine differently from older drugs and is expected in US pharmacies this month, the company says. For people with Parkinson’s disease, the same drug that gives ...

At LIC 2026, investors, scientists and founders examined what survives the journey from longevity hypothesis to human ...

Researchers say women in Bolotana are reaching 100 at rates that stand out even among the world’s longest-lived people.

Six of ten patients in a small trial improved by two or more steps on a severity scale after one treatment, though the data are interim. Most treatments for diabetic eye disease ask patients to come ...